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Abstract
Background: Continuous positive airway pressure (CPAP) treatment for acute cardiogenic pulmonary edema can have
important benefits in acute cardiac care. However, coronary care units are usually not equipped and their personnel not
adequately trained for applying CPAP with mechanical ventilators. Therefore we investigated in the coronary care unit
setting the feasibility and outcome of the simple Boussignac mask-CPAP (BCPAP) system that does not need a mechanical
ventilator.
Methods: BCPAP was introduced in a coronary care unit where staff had no CPAP experience. All consecutive patients
transported to our hospital with acute cardiogenic pulmonary edema, a respiratory rate > 25 breaths/min and a
peripheral arterial oxygen saturation of < 95% while receiving oxygen, were included in a prospective BCPAP group that
was compared with a historical control group that received conventional treatment with oxygen alone.
Results:  During the 2-year prospective BCPAP study period 108 patients were admitted with acute cardiogenic
pulmonary edema. Eighty-four of these patients (78%) were treated at the coronary care unit of which 66 (61%) were
treated with BCPAP. During the control period 66 patients were admitted over a 1-year period of whom 31 (47%)
needed respiratory support in the intensive care unit. BCPAP treatment was associated with a reduced hospital length
of stay and fewer transfers to the intensive care unit for intubation and mechanical ventilation. Overall estimated savings
of approximately € 3,800 per patient were achieved with the BCPAP strategy compared to conventional treatment.
Conclusion: At the coronary care unit, BCPAP was feasible, medically effective, and cost-effective in the treatment of
acute cardiogenic pulmonary edema. Endpoints included mortality, coronary care unit and hospital length of stay, need
of ventilatory support, and cost (savings).
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Background
Many cases of acute cardiogenic pulmonary edema
(ACPE) are treated with an oxygen mask and pharmaco-
logic treatment including diuretics and vasodilators [1,2].
When such treatment is not sufficient, additional ventila-
tory support may be useful [3,4]. Traditionally this has
been achieved via endotracheal intubation and mechani-
cal ventilation, an approach that usually requires inten-
sive care unit (ICU) admission. Continuous positive
airway pressure (CPAP) applied by a face mask is a feasi-
ble alternative. Several randomized clinical trials [5-8]
report a decreased rate of intubation and decreased hospi-
tal length of stay for patients assigned to mask-CPAP com-
pared with conventional therapy with oxygen alone.
These trials were performed either at the emergency
department or at the ICU and not in an environment such
as a coronary care unit (CCU) which is often not suited to
use mechanical ventilators that are normally necessary for
CPAP.
A simple CPAP device which does not require a ventilator
might therefore be useful to treat patients with ACPE in
the CCU and reduce the need for more invasive treatment
in the ICU. The Boussignac CPAP (BCPAP) system is a
small lightweight plastic cylinder that is directly con-
nected to a face mask which has been shown to be effec-
tive for ACPE in the emergency department and in
prehospital care [9,10]. Although no data are available on
the effectiveness of BCPAP in the CCU we found no con-
vincing medical arguments why BCPAP could not be
effective in the CCU. We hypothesized that the major
obstacle in treating patients with BCPAP in the CCU
would be organizational. We studied if implementation
of BCPAP in the CCU was practically feasible, medically
effective and cost reducing. For this purpose all patients
admitted to our hospital with ACPE were studied.
Methods
Boussignac CPAP system
The BCPAP face mask system (Vygon, 95440 Ecouen,
France) which is CE-approved and approved by the Food
and Drug Administration is a simple and lightweight (10
g) disposable cylindrical plastic device without sensors,
mechanical valves and without heavy tubing. A jet flow of
air and or oxygen generated in this plastic tube creates a
flow dependent pressure [9-14]. We used an air/oxygen
blender (Bird 3800™ Microblender, Palm Springs, USA)
for full control of the inspired oxygen fraction (FiO2).
BCPAP can generate a fraction of FiO2 that approaches
100% [11]. The generated pressure is proportional to the
flow applied: 3 cm H2O at a flow of 8 L/min, 5 cm H2O at
a flow of 15 L/min and 10 cm H2O at a flow of 23 L/min.
This was measured during CPAP treatment with a hand-
held electronic pressure analyzer (Testo 505-P1, Almere,
the Netherlands).
Patients
This study was conducted in a regional university hospital
with a 12 bed CCU and 4 ICU's with 47 beds. ACPE was
defined as acute dyspnea associated with a past of
ischemic heart disease or cardiomyopathy and physical
signs consistent with pulmonary edema including a respi-
ratory rate > 25 breaths/min and a peripheral arterial oxy-
gen saturation (SpO2) < 95% while receiving oxygen [3].
We studied all adult patients admitted to our hospital
with respiratory failure due to ACPE. Exclusion criteria
were known evidence of severe pulmonary pathology,
Glasgow coma scale < 9 and in the prospective group the
inability to wear a face mask (facial deviations, non-coop-
erative patient). The first ten patients treated with BCPAP
on the CCU were observed by the medical and nursing
staff of the ICU to ensure a safe and sufficient CPAP treat-
ment.
The institutional review board of the hospital approved
the study design that compared a historical control group
with a prospective BCPAP group. Verbal consent was
obtained and recorded from patients to use their medical
data. (METc 2004.195)
BCPAP group and control group
Patients in the intervention group received BCPAP with an
initial pressure of 10 cm H2O and an FiO2 of 80–100%.
BCPAP pressure and FiO2 were decreased when there was
a clinical improvement in SpO2 and heart rate. Patients
were preferably kept in a sitting position during BCPAP.
In order to facilitate successful implementation of BCPAP
both medical and nursing staff was involved in the imple-
mentation process. During a training session of 45 min-
utes we introduced the BCPAP system as well as a protocol
(Figure 1) for applying CPAP. The training session
included theory and practical use of CPAP and was dis-
tributed to all staff by an experienced ICU nurse according
a standardized teaching package to ensure consistency.
CCU staff was instructed to use BCPAP not for other indi-
cations than ACPE.
Data from the prospective BCPAP cohort of patients were
compared with the data from a historical control group.
The prospective part of the study was conducted over a
period of 24 months. Patients in the control group were
admitted in the same CCU and hospital in a previous 12
month period and treated with oxygen through non-
rebreathing mask (FiO2 approximately 100%), ventimask
(FiO2 40–60%) or nasal catheter (3 L/min; FiO2 30%) and
on ICU admission with endotracheal intubation. For this
purpose we evaluated all records from patients admitted
to the CCU and the ICU's for ACPE.BMC Cardiovascular Disorders 2007, 7:40 http://www.biomedcentral.com/1471-2261/7/40
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Data on pharmacological treatment with diuretics, opio-
ids and nitroglycerine as well as patient acceptance, com-
plications, SpO2, heart rate, CCU length of stay, hospital
length of stay, hospital mortality and long term mortality
were collected.
An economic evaluation was carried out to estimate costs
of the strategy that included BCPAP therapy compared
with conventional treatment. This evaluation was per-
formed from a hospital perspective, and all relevant costs
made between admission and discharge from the hospital
were taken into account. Where possible, costs were val-
ued according to Dutch standard prices [15]; if no stand-
ard prices were available, costs were estimated based on
true resources used and time invested by the hospital per-
sonnel. Cost categories included were: stay in CCU (€
1,112/day), stay in ICU (€ 1,733/day), admission to hos-
pital ward (€ 490/day), BCPAP therapy (€ 42), personnel
cost BCPAP therapy (€ 23) and endotracheal intubation
(€ 377). Based on costs of both conventional treatment
and BCPAP, and the percentages of patients admitted to
the CCU and ICU, total costs for both strategies were cal-
culated and compared.
Statistical analysis
Data are presented as medians and associated interquar-
tile ranges (IQR) or means with standard deviation (SD)
for continuous variables, or as group percentages for cate-
gorical variables. Statistical analysis was performed using
Student's t, Mann Whitney, Wilcoxon signed rank test,
Fisher exact or Chi-square test. Overall comparisons were
based on intention-to-treat: all patients treated at the CCU
or ICU for ACPE were compared between the control and
the BCPAP period, irrespective of whether they actually
received BCPAP. All statistical analyses were performed
using commercially available software (SPSS 14.0, SPSS,
Chicago, Illinois, USA).
Results
Sixty-six patients were included in the control group and
108 patients in the BCPAP group (Figure 2). Patients in
both study groups were predominantly male and had a
mean age of 72 years. Table 1 shows the characteristics of
both groups on an intention-to-treat basis. Pharmacolog-
ical treatment did not differ between the groups. Eighty-
four (78%) of the patients in the BCPAP group were
admitted to the CCU, of which 66 were actually treated
with BCPAP.
Algorithm for BCPAP treatment in patients with ACPE in the CCU Figure 1
Algorithm for BCPAP treatment in patients with ACPE in the CCU. Protocol as used for patients treated with 
BCPAP in the CCU. Since ACPE should respond within 30 minutes to BCPAP therapy, this protocol required early and fre-
quent assessments of the patients' response. From left to right the duration of BCPAP treatment is displayed and from top to 
bottom the decreasing level of respiratory support. CR: clinical response is defined as an improvement in respiration rate and 
SpO2 to at least > 95%. Success was defined as achievement of CR with breathing oxygen through a ventimask. Note that, 
depending on the patients' response the protocol leads to a minimal duration of BCPAP of 30 minutes and a maximal duration 
of 2 hours.
CPAP 10 cm H20 
FiO2 1.0
CPAP 5 cm H20 
FiO2 1.0
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No problems in the practical use of the BCPAP system
were identified. Eighteen patients who were admitted to
the CCU were eligible for BCPAP but did not receive this
treatment and received oxygen alone. The main reason
was because there were insufficient signs of serious respi-
ratory distress and staff believed that the patients (base-
line SpO2  91%. IQR 88–93) showed adequate
spontaneous improvement. The median duration of
BCPAP treatment was 105 minutes (IQR 60–172 min-
utes). Pressure measurements showed a predicted CPAP
level in 76% of the BCPAP patients. In only two patients
a flow of more than 23 L/min had to be given to achieve
the desired BCPAP level. Sixty-four of 66 patients main-
tained stable gas exchange after BCPAP was stopped. Two
of the 66 patients required follow-up respiratory support
in the ICU after BCPAP treatment in the CCU. One patient
with a large myocardial infarction and support with an
intra-aortic balloon pump had to be intubated and the
other received ventilator mask-CPAP. No other complica-
tions of the BCPAP treatment were reported and 88% of
the staff assessed the implementation of BCPAP as simple
and uncomplicated.
Saturation and heart rate
Baseline median SpO2 was lower in the BCPAP group than
in the control group (88% versus 91%, p < 0.01). Both
groups showed a significant increase in SpO2 after 2 hours
(Table 2). Nevertheless the increase of SpO2 was higher in
the BCPAP group compared to the control group (+8%
versus +3%, p < 0.01) with a similar SpO2 after 2 hours.
Heart rate in the BCPAP group was significantly decreased
after 2 hours of treatment (median 104/min to 86/min),
in contrast to the unchanged heart rate in the control
group (median 102). In the 2 to 6 hours after discontinu-
Study design Figure 2
Study design. First all patients with ACPE were examined at the emergency department by a cardiologist and depending on 
his findings transferred to CCU or ICU. The control group consisted of all patients admitted to our hospital with ACPE over a 
one year period. The BCPAP group covered all patients with ACPE over a two year period. Note the considerable shift of ICU 
admissions to CCU admissions in the BCPAP group (p < 0.001). The number of patients treated with BCPAP in the control 
group was zero since this option was then not available.
Control Group
66 patients
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ation of BCPAP, the saturation or heart rate did not dete-
riorate again.
Intubations, length of stay and outcome
After implementing BCPAP on the CCU, the number of
intubations showed an absolute decrease of 14% (p <
0.001) compared to the control period with conventional
treatment. Likewise the number of ICU admissions
showed an absolute decrease of 25% (p < 0.001) com-
pared to the control period.
The median CCU-stay in de BCPAP group was 1 day with
a median hospital length of stay of 6 days. In the control
group the median CCU-stay was 2 days and the median
hospital length of stay was 14 days. There was no signifi-
cant difference between the mortality rates in both groups
(BCPAP 22% versus control 24%).
Costs
As a shift was found in route of admittance, resulting in
more patients in the BCPAP group admitted to the CCU
compared to the ICU, costs changed accordingly. In the
control group, mean total costs for ACPE patients were €
13,754 per patient.
In the BCPAP group (where 61% of the patients actually
received BCPAP) mean total costs were € 9,968. This
resulted in a saving of € 3,787 per candidate for the new
treatment strategy compared to the traditional strategy.
Discussion
We demonstrated that for patients with acute cardiogenic
pulmonary edema it is possible to use a simple form of
mask-CPAP. The introduction of BCPAP at our CCU
decreased endotracheal intubations and the related ICU
admissions. Our study also underscores that CPAP, as
delivered by mask, is superior to conventional oxygen
treatment in improving oxygenation and decreasing heart
rate. Moreover, no complications were observed with the
use of the BCPAP system on our CCU. The decreasing
number of endotracheal intubations with related ICU
admissions after implementation of BCPAP on our CCU
led to notable cost reductions. Savings were approxi-
mately  € 3,800 per candidate for the strategy that
included BCPAP compared to the conventional strategy.
The treatment of ACPE with non-invasive CPAP was
already described in de first half of the previous century by
both Poulton [16] and Barach [17]. Nowadays there is
extensive evidence that supports the use of non-invasive
CPAP [7,1]. CPAP delivered by mask was shown to be
beneficial in several randomized clinical trials [5-8] as
stated in the introduction. However, these studies were
not performed at a CCU or a likewise environment. In
general CPAP together with pharmacological therapy
achieves rapid clinical improvement but heart failure – of
which ACPE is a cardinal manifestation – is still associated
with high in-hospital mortality and a poor long-term
prognosis [18], as also is seen in our patients (Table 1).
ACPE patients show significant improvement in the
PaO2/FiO2 ratio, subjective dyspnea score, and respiratory
and heart rates with CPAP [19,20]. At the same time CPAP
can reduce venous return, decrease ventricular filling pres-
sures and improve cardiac performance. In our patients,
CPAP produced a rapid physiological and symptomatic
Table 1: Patient characteristics
Control BCPAP p-value
N6 6 1 0 8
Duration of the study 1 year 2 years
Age in yrs, mean, ± SD 72 ± 11 72 ± 11 -
Male, n (%) 46 (70) 69 (64) -
Medication, n (%)
Loop-diuretics 56 (85) 97 (90) -
Opioids 34 (51) 47 (44) -
Nitroglycerine 29 (44) 39 (36) -
Admission CCU, n (%) 35 (53) 84 (78) < 0.01
Admission ICU, n (%) 31 (47) 24 (22) < 0.01
CCU stay in days, median (IQR) 3 (2–5) 2 (2–3) -
CCU stay in days, mean (SD) 2.0 (2.3) 2.3 (2.7) -
ICU stay in days, median (IQR) 2 (2–5) 4 (2–7) < 0.01
ICU stay in days, mean (SD) 2.0 (3.5) 1.3 (3.4) -
Hospital stay in days, median 
(IQR)
16 (8–24) 8 (2–16) < 0.01
Hospital stay in days, mean (SD) 20.2 (23.5) 13.9 (17.9) 0.047
Hospital survivors, n of total (%) 50 (76) 84 (78) -
6 month survival, n of total (%) 49 (74) 81 (75) -
Comparison of the two patients groups studied with intention-to-
treat analysis. The median CCU and ICU stay is only given for those 
patients who were admitted to the CCU and ICU respectively. In 
contrast, the mean CCU and ICU stay are calculated for the whole 
group. Comparisons were performed with the Fisher exact test, Chi-
square test, Student-t test and the Mann Whitney test. IQR = 
Interquartile range.
Table 2: Physiological responses before and after BCPAP in 
subgroup of CCU patients.
Control BCPAP p-value
N3 5 8 4
Heart rate baseline 102 (83–125) 104 (86–119) -
Heart rate after 120 min 102 (82–117) 86 (76–99)* 0.03
Mean arterial pressure 
baseline
101 (85–118) 103 (79–123) -
SpO2 baseline 91 (88–94) 88 (82–92) < 0.01
SpO2 after 120 min 94 (92–95)* 95 (92–97)* -
Data are median (IQR), SpO2 = peripheral arterial oxygen saturation. 
The Wilcoxon signed rank test was used to test differences between 
data collected at baseline and after 120 minutes. * Significant (p < 
0.05) within group improvement at 120 minutes compared to 
baseline.BMC Cardiovascular Disorders 2007, 7:40 http://www.biomedcentral.com/1471-2261/7/40
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improvement in patients with ACPE, especially within the
first hours, as also been observed with other CPAP modal-
ities [21]. More complicated forms of non-invasive venti-
lation, as bilevel ventilation, showed no additional
benefits in the treatment of ACPE compared to CPAP
[7,22]. Therefore, clinicians must be aware that if a rapid
physiological and symptomatic improvement does not
occur, the etiology of respiratory insufficiency might not
be acute cardiogenic pulmonary edema. In fact our proto-
col allowed no more than 120 minutes of BCPAP treat-
ment because other causes for respiratory distress may
then be present and intubation might be more appropri-
ate in this setting.
A tight fitted facemask can cause discomfort but it is fun-
damental for achieving adequate positive pressure in the
airways during CPAP. The patients at our CCU were sys-
tematically queried about their experiences with BCPAP
treatment and they found that the reduction of dyspnea
outweighed any discomfort of the facemask. These find-
ings were exemplified by a patient who was successfully
treated during many episodes of ACPE with BCPAP:
although initially wary about a facemask he subsequently
easily accepted it for many times [23]. Although most
nurses in our CCU had limited expertise and experience in
the field of mask-CPAP they could apply BCPAP effec-
tively after a short instruction period.
The effectiveness of BCPAP has also been demonstrated in
prehospital settings [9]. Future studies focusing on the
early administration of BCPAP in patients with ACPE – in
a pre-hospital setting such as an ambulance – would add
insight into the clinical advantages and cost benefits of
early CPAP treatment of patients with ACPE.
There are some limitations of the present study. First, the
data from the control group is retrospective and ACPE is
not always easy to diagnose. Based on the evaluation of all
patient records great care was taken to include all patients
who were admitted to our hospital with ACPE according
to established criteria [3]. Second, in the prospective
BCPAP group the treatment of patients might have dif-
fered slightly due to ongoing advances in treatment of
patients with ACPE. For comparison, treatment of
patients with ST-elevation myocardial infarction
improved because of more widespread and rapid use of
percutaneous coronary intervention. But in the treatment
of ACPE no major or minor changes in the treatment have
occurred in our institution. Finally, calculated savings
were based on assumptions that are related with the reim-
bursement system in the Netherlands and therefore
should be interpreted with caution when transposed to
other institutions.
Conclusion
The results of this study underscore the utility of the Bous-
signac CPAP system as a simple, effective and cost saving
modality on a CCU for patients with ACPE.
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